Skip to main content

IBRX

Stock
Health Care
Biotechnology

Performance overview

IBRX Price
Price Chart

Forward-looking statistics

Beta
2.22
Risk
100.00%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

ImmunityBio Inc is a late-clinical-stage immunotherapy company developing next-generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. Geographically, the company operates in United States and Europe. Majority of the revenue is generated from Europe.

Company info

SectorHealth Care
IndustryBiotechnology
Employees581
Market cap$4.2B

Fundamentals

Enterprise value$3.1B
Revenue$31.2M
Revenue per employee—
Profit margin100.00%
Debt to equity-1.39

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$0.57
Dividend per share—
Revenue per share$0.04
Avg trading volume (30 day)$26M
Avg trading volume (10 day)$18M
Put-call ratio—

Macro factor sensitivity

Growth-3.2
Credit+10.1
Liquidity+2.3
Inflation-8.7
Commodities-0.4
Interest Rates-2.6

Valuation

Dividend yield0.00%
PEG Ratio-4.32
Price to sales76.89
P/E Ratio-4.32
Enterprise Value to Revenue99.03
Price to book-3.93

Upcoming events

Next earnings dayMay 12, 2025
Next dividend day—
Ex. dividend day—

News

ImmunityBio (IBRX) Moves to Buy: Rationale Behind the Upgrade

ImmunityBio (IBRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Investment Research (May 15, 2025)
ImmunityBio Slapped With FDA Refusal To File Letter For Expanded Use Of Its Bladder Cancer Drug

ImmunityBio, Inc. IBRX on Monday received a Refusal to File (RTF) letter from the U.S. Food and Drug Administration (FDA) for the supplemental biologics license application (sBLA) for use of ANKTIVA plus Bacillus Calmette-Guerin (BCG) in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) for the indication of papillary disease.

Benzinga (May 5, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free